论文部分内容阅读
促红细胞生成素 (erythropoietin ,EPO)是由肾脏产生的一种可以调节红细胞生成的激素。受缺氧、贫血刺激而变化 ,血清EPO浓度在妊娠期较非妊娠妇女高 ,妊娠合并贫血时 ,EPO的分泌水平更高 ,且与血红蛋白 (Hb)、红细胞比容 (Hct)呈负相关 ,与红细胞生成呈正相关。同时妊娠合并缺铁性贫血 (IDA)时 ,EPO与血清铁蛋白 (SF)及血清转缺铁蛋白受体 (sTfR)存在一定的关系。通过对EPO与妊娠合并缺铁性贫血关系的研究进展 ,为临床使用重组人促红细胞生成素 (rhuEPO)治疗妊娠合并缺铁性贫血 (IDA)提供了理论基础。
Erythropoietin (EPO) is a hormone produced by the kidneys that regulates erythropoiesis. Affected by hypoxia and anemia, serum EPO concentration was higher in pregnant women than in non-pregnant women. EPO secretion was higher in pregnancy with anemia, and negatively correlated with hemoglobin (Hb) and hematocrit (Hct) And erythropoiesis was positively correlated. At the same time pregnant with iron deficiency anemia (IDA), EPO and serum ferritin (SF) and serum transfer to ferritin receptor (sTfR) there is a certain relationship. The research progress on the relationship between EPO and iron deficiency anemia in pregnancy provides a theoretical basis for clinical use of recombinant human erythropoietin (rhuEPO) in the treatment of iron deficiency anemia (IDA) in pregnancy.